UroGen Pharma (URGN) Interest Coverage Ratio Growth (1y) (2018 - 2026)
UroGen Pharma (URGN) Interest Coverage Ratio Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -347.04% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 73.00% |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn | 97.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.80% |
| Dec 31, 2025 | 37.97% |
| Sep 30, 2025 | 71.30% |
| Jun 30, 2025 | 55.88% |
| Mar 31, 2025 | -80.57% |
| Dec 31, 2024 | -151.56% |
| Sep 30, 2024 | -146.89% |
| Jun 30, 2024 | 93.33% |
| Mar 31, 2024 | -1,027.99% |
| Dec 31, 2023 | 27.23% |
| Sep 30, 2023 | -15.58% |
| Jun 30, 2023 | -364.69% |
| Mar 31, 2023 | 88.89% |
| Dec 31, 2022 | -596.74% |
| Jun 30, 2022 | 99.16% |
| Mar 31, 2022 | -512.71% |
| Dec 31, 2021 | 121.40% |
| Mar 31, 2021 | 83.08% |
| Dec 31, 2020 | -45.78% |
| Sep 30, 2020 | -770.35% |